Institute for Drug Development

San Antonio, Texas 78245-3217

0 studies enrolling now · 12 studies all time

What they study most

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Advanced Nonhematologic Malignancies, Brain and Central Nervous System Tumors, Cancer, Colorectal Cancer, Lymphoma, Melanoma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Prostate Cancer, Recurrent Renal Cell Carcinoma

Studies at this site

• SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors — Completed
• Vorinostat in Treating Patients With Kidney Cancer — Completed
• An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 — Completed
• Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors — Completed
• MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia — Completed
• Study of MLN4924 in Adult Patients With Nonhematologic Malignancies — Completed
• Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer — Completed
• ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer — Completed
• Chemotherapy in Treating Patients With Prostate Cancer — Completed
• DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas — Completed
• Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma — Completed
• CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma — Completed